NCT05414071

Clinical Investigation of NMS Assist

Withdrawn NA Last updated 22 June 2025

What this trial tests

NA trial testing NMS Assist in Parkinson. Withdrawn.

Timeline

1 December 2023

Primary endpoint
1 March 2025

1 March 2025

Quick facts

Lead sponsor	University of Plymouth
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Start date	1 December 2023
Primary completion	1 March 2025
Estimated completion	1 March 2025

Drugs / interventions tested

• NMS Assist

Conditions studied

• Parkinson — all drugs for Parkinson →

Sponsor

University of Plymouth

Who can join

18 and older, any sex, with Parkinson. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parkinson's can cause a wide range of non-motor symptoms (NMS), including pain and problems with mental health, memory and sleep. These affect the quality of life of people with Parkinson's (PwP) and their care partners (CP). If these issues are not recognised and managed quickly, they can result in escalating problems. Many PwP are unsure of the extent and variety of the NMS and how simple adjustments at home could improve them. We have developed a digital system, NMS Assist, to help PwP monitor their non-motor symptoms and develop skills to self-manage them.

Such a tool needs to be simple to use, safe and effective. We will ask 60 PwP, CP and members of their Parkinson's healthcare team to use NMS Assist for 12 months, and we will monitor how they use the tool. PwP and CPs will be asked if they feel more knowledgeable and confident to manage their own symptoms whilst being better able to discuss a problem with their healthcare professional.

A smaller group of the participants will discuss their experiences in more detail to help pinpoint aspects that work well and those needing adjustment and development. Members of the healthcare team will be asked to assess any improvement in communication with PwP and CPs.

It is thought that the use of this system will result in improved quality of life and increased knowledge and confidence for managing symptoms while safely reducing the time spent by health care professionals on manageable non-motor symptoms.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Nonmotor Symptoms in People With Parkinson Disease: Proposal for a Phase 1 Implementation Study.
   Meinert E, Milne-Ives M, Chaudhuri KR, Harding T, et al · · 2022 · cited 6× · PMID 36155396 · DOI 10.2196/40317